New combo therapy shows promise for Tough-to-Treat lymphoma
NCT ID NCT05583149
First seen Feb 01, 2026 · Last updated Apr 29, 2026 · Updated 15 times
Summary
This study tests whether adding the drug acalabrutinib to a CAR-T cell therapy (lisocabtagene maraleucel) can improve outcomes for people with aggressive B-cell lymphoma that has returned or not responded to prior treatment. About 28 adults will receive the combination, and researchers will measure how many achieve complete remission. The goal is to find a more effective treatment for this hard-to-treat cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beth-Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.